EGFR and non-small cell lung carcinoma: In addition to determining the safety and efficacy of erlotinib plus onalespib in a phase I dose escalation trial in EGFR-mutant NSCLC, the phase II portion of this study sought to explore whether combination strategies with HSP90 inhibition and EGFR TKIs may increase activity specifically in EGFRex20ins NSCLC.